Perhaps more significantly, the recognition of imatinib activity against other kinases, notably KIT and PDGFR (platelet-derived growth factor receptor), has led to its effective use in other oncology indications [46,47] and ongoing clinical trials in fibrosis [48]. Here, KIT is linked to fibrosis.